NKT and B1 (MHCII+, CD19+, CD11b+) cells are of emerging interest in the immune-oncology field as these cells have the potential to mount a direct cancer cell death response, so they are part of the adaptive immune response and they have an innate immune response component [41,55]. This evidence concerns the gene CD19 and cancer.